Central sleep apnea (CSA) is common in patients with heart failure. Recent studies link ticagrelor use with CSA. We aimed to evaluate CSA prevalence in patients with coronary heart disease (CHD) and whether ticagrelor use is associated with CSA. We reviewed consecutive patients with CHD who underwent a polysomnography (PSG) test over a 5-year period from 3 sleep centers. We sampled patients who were on ticagrelor or clopidogrel during a PSG test at a 1:4 ticagrelor:clopidogrel ratio. Patients with an active opioid prescription during PSG test were excluded. Age, left ventricle (LV) dysfunction, and P2Y12 inhibitor use were included in a multivariate logistic regression. A total of 135 patients were included with 26 on ticagrelor and 109 on clopidogrel (age 64.1 ± 11.4, 32% male). High CSA burden (12%) and strict CSA (4.4%) were more common in patients on ticagrelor than in those on clopidogrel (27% vs. 8.3% and 10.0% vs. 1.8%). Ticagrelor use (vs. clopidogrel) was associated with high CSA burden (OR 3.53, 95% CI 1.04-12.9, P = 0.039) and trended toward significance for strict CSA (OR 6.32, 95% CI 1.03-51.4, P = 0.052) when adjusting for age and LV dysfunction. In an additional analysis also adjusting for history of atrial fibrillation, ticagrelor use and strict CSA became significantly associated (OR 10.0, 95% CI 1.32-117, P = 0.035). CSA was uncommon in patients with CHD undergoing sleep studies. Ticagrelor use (vs. clopidogrel) was associated with high CSA burden and trended toward significance for strict CSA.

中文翻译：

---

服用 P2Y12 抑制剂的冠心病患者出现中枢性睡眠呼吸暂停。

中枢性睡眠呼吸暂停（CSA）在心力衰竭患者中很常见。最近的研究将替格瑞洛的使用与 CSA 联系起来。我们的目的是评估冠心病 (CHD) 患者的 CSA 患病率以及替格瑞洛的使用是否与 CSA 相关。我们对 3 个睡眠中心连续 5 年接受多导睡眠图 (PSG) 测试的先心病患者进行了回顾。我们以 1:4 的替格瑞洛：氯吡格雷比例对 PSG 测试期间服用替格瑞洛或氯吡格雷的患者进行了抽样。在 PSG 测试期间服用有效阿片类药物处方的患者被排除在外。年龄、左心室 (LV) 功能障碍和 P2Y12 抑制剂的使用均包含在多变量逻辑回归中。总共 135 名患者被纳入其中，其中 26 名患者使用替格瑞洛，109 名患者使用氯吡格雷（年龄 64.1 ± 11.4，32% 为男性）。服用替格瑞洛的患者比服用氯吡格雷的患者更常见高 CSA 负担 (12%) 和严格 CSA (4.4%)（27% vs. 8.3% 和 10.0% vs. 1.8%）。替格瑞洛的使用（相对于氯吡格雷）与高 CSA 负担相关（OR 3.53，95% CI 1.04-12.9，P = 0.039），并且对严格 CSA 具有显着意义（OR 6.32，95% CI 1.03-51.4，P = 0.052）当调整年龄和左心室功能障碍时。在另一项分析中，还调整了房颤病史，替格瑞洛的使用和严格的 CSA 显着相关（OR 10.0，95% CI 1.32-117，P = 0.035）。CSA 在接受睡眠研究的 CHD 患者中并不常见。替格瑞洛的使用（相对于氯吡格雷）与高 CSA 负担相关，并且对严格的 CSA 具有重要意义。